CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and best-in-class programs into clinical development Jan. 09, 2025 -- Numab Therapeutics AG (“Numab”), a clinical stage biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, announced today the closing of an oversubscribed CHF 50 million (approx

VG901 is the first-in-class and only clinical-stage therapy designed to deliver the functional CNGA1 gene intravitreally (IVT) to target retinal photoreceptor cells in patients with retinitis pigmentosa FDA Rare Pediatric Disease Designation qualifies ViGeneron for potential eligibility for a Priority Review Voucher (PRV) upon marketing approval The independent Data Safety Monitoring Board (DSMB) unanimously approved dose escalation in VG901’s ongoing Phase 1b clinical trial Jan. 08, 2025 -- Vi

Jan. 08, 2025 -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment of individuals with Hunter syndrome (MPS II). This designation is in addition to Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation, all previously granted by the FDA for tividenofusp alfa in Hunter syndrome. Denali expects to submit a Biologics

– IND for QTX3544 is third for Quanta within one year – – Initiated combination portion of Phase 1 clinical trial of QTX3046, an oral KRASG12D-selective dual ON/OFF state allosteric inhibitor, with the EGFR inhibitor cetuximab – – Phase 1 clinical trial of QTX3034, oral G12D-preferring multi-KRAS progressing; data readout anticipated in 2025 – Jan. 08, 2025 -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative, oral therapeutics

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide,

Jan. 08, 2025 -- Mirror Biologics, Inc., specializing in development and manufacturing of immunotherapy products where the active ingredient is living, non-genetically altered, allogeneic (“off-the-shelf”) immune cells, announces that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany. The parties will collaborate to conduct a Phase II clinical trial to evaluate the combination of an experimental immunotherapy drug, AlloStim® from Mirror

Angelini Ventures co-leads alongside Invivo Partners with participation from Innovestor’s Life Science Fund and other existing investors Financing will support clinical development of Neumirna‘s lead asset NMT.001, a potential disease-modifying Antisense Oligonucleotide (ASO) therapy for drug-resistant epilepsy, as well as expand its R&D capabilities and scale its pioneering drug discovery platform Angelini Venture’s investment in Neumirna marks its 5th in the field of neurological disorders and

Jan. 08, 2025 -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for PYRUKYND® (mitapivat) for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The review classification for this application is Sta

Initial clinical observations suggest high level of T cells reprogramming and CAR-T expansion at the starting dose without lymphodepletion At 28 days after a single dose of ESO-T01, no cancer cells were detected in the bone marrow ESO-T01 is being developed in collaboration with Shenzhen Pregene Biopharma Jan. 08, 2025 -- EsoBiotec SA, a biotechnology company empowering cells in vivo to fight cancer, in collaboration with Pregene Biopharma, today announced the first patient has been dosed in a

Successfully dosed 6 patients in safety run-in segment, now accelerating enrollment Positive data from first four patients announced December 2024 NXC-201 is the only one-time CAR-T therapy in development for AL Amyloidosis Next program update Q1 2025 AL Amyloidosis is a life-threatening disorder of plasma cells in the bone marrow affecting ~33,000 patients in the U.S. Jan. 07, 2025 -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”), a clinical-stage biopharma